Innovation, aging, and health care: Unraveling “silver” from “red” herrings?
Author
Abstract
Suggested Citation
DOI: 10.1002/hec.4187
Download full text from publisher
References listed on IDEAS
- Francesca Barigozzi & Izabela Jelovac, 2020.
"Research funding and price negotiation for new drugs,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 83-96, October.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers 1901, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Francesca Barigozzi & Izabela Jelovac, 2020. "Research funding and price negotiation for new drugs," Post-Print halshs-02910863, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148454, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409768, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Working Papers halshs-01987643, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02148462, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409743, HAL.
- Francesca Barigozzi & Izabela Jelovac, 2019. "Research funding and price negotiation for new drugs," Post-Print halshs-02409758, HAL.
- Julien Hugonnier & Florian Pelgrin & Pascal St‐Amour, 2020.
"Closing down the shop: Optimal health and wealth dynamics near the end of life,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(2), pages 138-153, February.
- Hugonnier, J. & Pelgrin, F. & St-Amour, P., 2016. "Closing Down the Shop: Optimal Health and Wealth Dynamics near the End of Life," Health, Econometrics and Data Group (HEDG) Working Papers 16/28, HEDG, c/o Department of Economics, University of York.
- Julien Hugonnier & Florian Pelgrin & Pascal St-Amour, 2017. "Closing Down the Shop: Optimal Health and Wealth Dynamics Near the End of Life," Swiss Finance Institute Research Paper Series 17-11, Swiss Finance Institute, revised May 2018.
- DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
- Domenico Depalo, 2020.
"Explaining the causal effect of adherence to medication on cholesterol through the marginal patient,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 110-126, October.
- Depalo, D.;, 2019. "Explaining the causal effect of adherence to medication on cholesterol through the marginal patient," Health, Econometrics and Data Group (HEDG) Working Papers 19/13, HEDG, c/o Department of Economics, University of York.
- Rosella Levaggi & Paolo Pertile, 2020. "Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition," Applied Health Economics and Health Policy, Springer, vol. 18(3), pages 357-362, June.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Levaggi, Rosella, 2014. "Pricing schemes for new drugs: A welfare analysis," Social Science & Medicine, Elsevier, vol. 102(C), pages 69-73.
- Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.
- G. M.P. Swann, 2009. "The Economics of Innovation," Books, Edward Elgar Publishing, number 13211.
- Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik, 2016.
"Late-stage pharmaceutical R&D and pricing policies under two-stage regulation,"
Journal of Health Economics, Elsevier, vol. 50(C), pages 298-311.
- Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman, 2015. "Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation," Discussion Papers 15/16, Department of Economics, University of York.
- Peter Zweifel & Lukas Steinmann & Patrick Eugster, 2005. "The Sisyphus Syndrome in Health Revisited," International Journal of Health Economics and Management, Springer, vol. 5(2), pages 127-145, June.
- Friedrich Breyer & Joan Costa-Font & Stefan Felder, 2010. "Ageing, health, and health care," Oxford Review of Economic Policy, Oxford University Press and Oxford Review of Economic Policy Limited, vol. 26(4), pages 674-690, Winter.
- repec:wly:hlthec:v:26:y:2017:i::p:106-126 is not listed on IDEAS
- Katharina Elisabeth Blankart & Tom Stargardt, 2020. "The impact of drug quality ratings from health technology assessments on the adoption of new drugs by physicians in Germany," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 63-82, October.
- Cinzia Di Novi & Lucia Leporatti & Marcello Montefiori, 2020. "Older patients and geographic barriers to pharmacy access: When nonadherence translates to an increased use of other components of health care," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 97-109, October.
- Carone, Giuseppe & Schwierz, Christoph & Xavier, Ana, 2012.
"Cost-containment policies in public pharmaceutical spending in the EU,"
MPRA Paper
42008, University Library of Munich, Germany.
- Giuseppe Carone & Christoph Schwierz & Ana Xavier, 2012. "Cost-containment policies in public pharmaceutical spending in the EU," European Economy - Economic Papers 2008 - 2015 461, Directorate General Economic and Financial Affairs (DG ECFIN), European Commission.
- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012. "Does Adoption of Pharmaceutical Innovation Respond to Changes in the Regulatory Environment?," Applied Economic Perspectives and Policy, Agricultural and Applied Economics Association, vol. 34(3), pages 531-553.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One lab, two firms, many possibilities : On R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02312319, HAL.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Joan Costa-Font & Elias Mossialos & Caroline Rudisill, 2009. "When is the Internet a valued communication device for health information in Europe?," Economics of Innovation and New Technology, Taylor & Francis Journals, vol. 18(5), pages 429-445.
- Valérie Paris & Marion Devaux & Lihan Wei, 2010. "Health Systems Institutional Characteristics: A Survey of 29 OECD Countries," OECD Health Working Papers 50, OECD Publishing.
- Vincenzo Atella & Federico Belotti & Domenico Depalo, 2017.
"Drug therapy adherence and health outcomes in the presence of physician and patient unobserved heterogeneity,"
Health Economics, John Wiley & Sons, Ltd., vol. 26(S2), pages 106-126, September.
- Vincenzo Atella & Federico Belotti & Domenico Depalo, 2011. "Drug therapy adherence and health outcomes in presence of physician and patient unobserved heterogeneity," CEIS Research Paper 186, Tor Vergata University, CEIS, revised 22 Jun 2017.
- Dyfrig A. Hughes & Adrian Bagust & Alan Haycox & Tom Walley, 2001. "The impact of non‐compliance on the cost‐effectiveness of pharmaceuticals: a review of the literature," Health Economics, John Wiley & Sons, Ltd., vol. 10(7), pages 601-615, October.
- Rosella Levaggi & Paolo Pertile, 2020. "Which valued‐based price when patients are heterogeneous?," Health Economics, John Wiley & Sons, Ltd., vol. 29(8), pages 923-935, August.
- Nebibe Varol & Joan Costa-Font & Alistair McGuire, 2012. "Does Adoption of Pharmaceutical Innovation Respond to Changes in the Regulatory Environment?," Applied Economic Perspectives and Policy, Agricultural and Applied Economics Association, vol. 34(3), pages 531-553.
Citations
Blog mentions
As found by EconAcademics.org, the blog aggregator for Economics research:- Chris Sampson’s journal round-up for 28th December 2020
by Chris Sampson in The Academic Health Economists' Blog on 2020-12-28 12:00:00
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Lucia Leporatti & Rosella Levaggi & Marcello Montefiori, 2021. "Beyond price: the effects of non-financial barriers on access to drugs and health outcomes," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(4), pages 519-529, June.
- Watal, Jayashree & Dai, Rong, 2019. "Product patents and access to innovative medicines in a post-trips-era," WTO Staff Working Papers ERSD-2019-05, World Trade Organization (WTO), Economic Research and Statistics Division.
- Rosella Levaggi & Paolo Pertile, 2021. "A reply to “Who would benefit from average value‐based pricing?”," Health Economics, John Wiley & Sons, Ltd., vol. 30(9), pages 2284-2286, September.
- Simona Gamba & Laura Magazzini & Paolo Pertile, 2019. "R&D and market size: who benefits from orphan drug regulation?," Working Papers 09/2019, University of Verona, Department of Economics.
- Di Novi, Cinzia & Leporatti, Lucia & Levaggi, Rosella & Montefiori, Marcello, 2022. "Adherence during COVID-19: The role of aging and socio-economics status in shaping drug utilization," Journal of Economic Behavior & Organization, Elsevier, vol. 204(C), pages 1-14.
- Volker Grossmann, 2021. "Medical Innovations and Ageing: A Health Economics Perspective," CESifo Working Paper Series 9387, CESifo.
- Dai, Rong & Watal, Jayashree, 2021. "Product patents and access to innovative medicines," Social Science & Medicine, Elsevier, vol. 291(C).
- Domenico Depalo, 2020.
"Explaining the causal effect of adherence to medication on cholesterol through the marginal patient,"
Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 110-126, October.
- Depalo, D.;, 2019. "Explaining the causal effect of adherence to medication on cholesterol through the marginal patient," Health, Econometrics and Data Group (HEDG) Working Papers 19/13, HEDG, c/o Department of Economics, University of York.
- Costantini, Valeria & Sforna, Giorgia, 2020. "A dynamic CGE model for jointly accounting ageing population, automation and environmental tax reform. European Union as a case study," Economic Modelling, Elsevier, vol. 87(C), pages 280-306.
- Katharina E. Blankart & Frank R. Lichtenberg, 2020. "Are patients more adherent to newer drugs?," Health Care Management Science, Springer, vol. 23(4), pages 605-618, December.
- Kuhn, Michael & Frankovic, Ivan & Wrzaczek, Stefan, 2017.
"Medical Progress, Demand for Health Care, and Economic Performance,"
VfS Annual Conference 2017 (Vienna): Alternative Structures for Money and Banking
168249, Verein für Socialpolitik / German Economic Association.
- Frankovic, Ivan & Kuhn, Michael & Wrzaczek, Stefan, 2017. "Medical progress, demand for health care, and economic performance," ECON WPS - Working Papers in Economic Theory and Policy 08/2017, TU Wien, Institute of Statistics and Mathematical Methods in Economics, Economics Research Unit.
- Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
- Nicolas Houy & Izabela Jelovac, 2015.
"Drug Launch Timing and International Reference Pricing,"
Health Economics, John Wiley & Sons, Ltd., vol. 24(8), pages 978-989, August.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Working Papers halshs-00782179, HAL.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Post-Print halshs-00955848, HAL.
- Nicolas Houy & Izabela Jelovac, 2015. "Drug launch timing and international reference pricing," Post-Print halshs-00993816, HAL.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Working Papers 1301, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Nicolas Houy & Izabela Jelovac, 2013. "Drug launch timing and international reference pricing," Post-Print halshs-00861222, HAL.
- Izabela Jelovac & Nicolas Houy, 2014. "Drug launch timing and international reference pricing," Post-Print halshs-01088164, HAL.
- Nicolas Houy & Izabela Jelovac, 2014. "Drug launch timing and international reference pricing," Post-Print halshs-01096276, HAL.
- Domenico Depalo & Jay Bhattacharya & Vincenzo Atella & Federico Belotti, 2019. "When Technological Advance Meets Physician Learning in Drug Prescribing," NBER Working Papers 26202, National Bureau of Economic Research, Inc.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2019.
"One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry,"
Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
- Billette de Villemeur, Etienne & Versaevel, Bruno, 2017. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," MPRA Paper 76903, University Library of Munich, Germany.
- Etienne Billette de Villemeur & Bruno Versaevel, 2019. "One Lab, Two Firms, Many Possibilities: on R&D outsourcing in the biopharmaceutical industry," Post-Print hal-02107357, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960435, HAL.
- Bruno Versaevel, 2018. "One lab, two firms, many Possibilities: On R&D outsourcing in the biopharmaceutical industry," Post-Print halshs-01960426, HAL.
- Kurt R. Brekke & Dag Morten Dalen & Odd Rune Straume, 2022.
"The price of cost-effectiveness thresholds,"
NIPE Working Papers
5/2022, NIPE - Universidade do Minho.
- Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds," Discussion Paper Series in Economics 4/2023, Norwegian School of Economics, Department of Economics.
- Howell, Sabrina T. & Rathje, Jason & Van Reenen, John & Wong, Jun, 2021.
"Opening up Military Innovation: Causal Effects of 'Bottom-up' Reforms to U.S. Defense Research,"
IZA Discussion Papers
14297, Institute of Labor Economics (IZA).
- Sabrina T. Howell & Jason Rathje & John Van Reenen & Jun Wong, 2021. "Opening up military innovation: causal effects of 'bottom-up' reforms to U.S. defense research," CEP Discussion Papers dp1760, Centre for Economic Performance, LSE.
- Kamila Bielawska & Krzysztof Lyskawa, 2021. "Retirees’ Healthcare Needs and Satisfaction with their Coverage," European Research Studies Journal, European Research Studies Journal, vol. 0(2), pages 1007-1018.
- Nicolas Houy & Izabela Jelovac, 2014.
"Drug approval decision times, international reference pricing and strategic launches of new drugs,"
Working Papers
1425, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178630, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178636, HAL.
- Izabela Jelovac & Nicolas Houy, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01261578, HAL.
- Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01138229, HAL.
- Izabela Jelovac & Nicolas Houy, 2017. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01657274, HAL.
- Nicolas Houy & Izabela Jelovac, 2014. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Working Papers halshs-01072741, HAL.
- Izabela Jelovac, 2015. "Drug approval decision times, international reference pricing and strategic launches of new drugs," Post-Print halshs-01178631, HAL.
- Billette de Villemeur, Etienne & Scannell, Jack & Versaevel, Bruno, 2021.
"Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?,"
MPRA Paper
108233, University Library of Munich, Germany.
- Jack Scannell & Bruno Versaevel & Etienne Billette de Villemeur, 2022. "Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?," Post-Print hal-03967759, HAL.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:wly:hlthec:v:29:y:2020:i:s1:p:3-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www3.interscience.wiley.com/cgi-bin/jhome/5749 .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.